January 1, 2021Open Access

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations

Key Points

Key points are not available for this paper at this time.

Abstract

Combination of TKI/anti-PD-1 antibodies is a feasible conversion therapy for patients with unresectable HCC to become resectable. This study represents the largest patient cohort on downstaging role of combinational systemic therapy on TKI and PD-1 antibody for HCC.

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Zhu et al. (Fri,) studied this question.

synapsesocial.com/papers/69d8e7a113e0539d74bedfef https://doi.org/https://doi.org/10.1159/000514313

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update2016 · 394 citations
2A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).2018 · 124 citations
3Cancer statistics, 20162016 · 16,153 citations
4Surgical Management of Liver Metastases From Colorectal Cancer2016 · 74 citations
5Sorafenib in Advanced Hepatocellular Carcinoma2008 · 5,615 citations

Perguntar à IA

Bookmark

View Full Paper